Ultimovacs AS Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.04.22	Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting (GlobeNewswire)
30.03.22	Ultimovacs to host Investor Days 2022: Meet the Team (GlobeNewswire)
25.03.22	Correction: Ultimovacs ASA: Annual Report 2021 (GlobeNewswire)
25.03.22	Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022 (GlobeNewswire)
25.03.22	Ultimovacs ASA: Annual Report 2021 (GlobeNewswire)
21.03.22	Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma (GlobeNewswire)
09.03.22	Ultimovacs to Present Preclinical Data on TET Platform at American Association for Cancer Research (AACR) 2022 Annual Meeting (GlobeNewswire)
17.02.22	Ultimovacs ASA: Mandatory notification of trade by primary insider (GlobeNewswire)
17.02.22	Ultimovacs ASA: Fourth quarter 2021 result presentation (GlobeNewswire)
10.02.22	Ultimovacs ASA: Invitation to fourth quarter 2021 results webcast presentation (GlobeNewswire)
03.02.22	Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study (GlobeNewswire)
15.12.21	First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer (GlobeNewswire)
02.12.21	Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma (GlobeNewswire)
02.12.21	Ultimovacs ASA: Mandatory notification of trade by primary insider (GlobeNewswire)
29.11.21	Ultimovacs ASA: Mandatory notification of trade by primary insider (GlobeNewswire)
25.11.21	Ultimovacs ASA: Mandatory notification for close associate (GlobeNewswire)
11.11.21	Ultimovacs ASA: Third quarter 2021 result presentation (GlobeNewswire)
09.11.21	Ultimovacs’ SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma (GlobeNewswire)
03.11.21	Ultimovacs ASA: Invitation to third quarter 2021 results presentation (GlobeNewswire)
02.11.21	Ultimovacs ASA – New share capital registered (GlobeNewswire)
27.10.21	Ultimovacs ASA – Transactions by primary insiders and closely associated parties (GlobeNewswire)
27.10.21	Ultimovacs ASA - Private placement of new shares successfully placed (GlobeNewswire)
26.10.21	Ultimovacs ASA - Contemplated private placement (GlobeNewswire)
26.10.21	Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC) (GlobeNewswire)
21.10.21	Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma (GlobeNewswire)
15.10.21	Ultimovacs ASA: New share capital registered (GlobeNewswire)
13.10.21	Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma (GlobeNewswire)
12.10.21	Ultimovacs ASA: Share capital increase related to exercise of options (GlobeNewswire)
08.10.21	Ultimovacs ASA announces Two Key Appointments to the Management Team as the Operations Advances (GlobeNewswire)
01.10.21	Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine (GlobeNewswire)
20.08.21	Ultimovacs ASA: Second quarter 2021 result presentation (GlobeNewswire)
12.08.21	Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma (GlobeNewswire)
11.08.21	Ultimovacs ASA: Invitation to second quarter 2021 results webcast presentation (GlobeNewswire)
05.08.21	Ultimovacs announces first patient enrolled in Phase II FOCUS trial of UV1 in head-and-neck cancer (GlobeNewswire)
05.07.21	Ultimovacs’ Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines (GlobeNewswire)
04.06.21	Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program (GlobeNewswire)
11.05.21	Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology (Businesswire)
11.05.21	Ultimovacs ASA: First Quarter 2021 Result Presentation (Businesswire)
10.05.21	Ultimovacs to Discuss ASCO UV1 Phase I Data in Webcast and Investor Meetings (Businesswire)
28.04.21	Ultimovacs Announces UV1 Data Presentation at Upcoming 2021 ASCO Annual Meeting (Businesswire)
10.04.21	Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021 (Businesswire)
18.02.21	Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine (Businesswire)
17.02.21	Ultimovacs ASA: Fourth Quarter 2020 Result Presentation (Businesswire)
28.01.21	Ultimovacs Announces NIPU Trial Design Poster Presented at World Conference of Lung Cancer Singapore 2020 (Businesswire)
22.12.20	Ultimovacs ASA Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab (Businesswire)
10.12.20	Ultimovacs Announces Positive 5-Year Overall Survival Update from Phase I Combination Trial Evaluating Universal Cancer Vaccine UV1 in Metastatic Melanoma (Businesswire)
24.11.20	Ultimovacs Announces the Appointment of Ton Berkien as Chief Business Officer (Businesswire)
12.11.20	Ultimovacs Announces Third Quarter 2020 Result Presentation (Businesswire)
02.11.20	Ultimovacs Announces Acceptance of Publication in ‘Frontiers in Immunology’ Featuring Positive Results From Phase I Trial Evaluating UV1 in Non-Small Cell Lung Cancer (Businesswire)
19.10.20	Ultimovacs Announces Updated Positive Results from Phase I Trial Evaluating Universal Cancer Vaccine, UV1, in Non-Small Cell Lung Cancer (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Ultimovacs AS Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten